JAKAFIRuxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer
The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.
The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.
Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer
The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.
The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.
Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer
The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.
The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.
Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer
The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.
The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.
Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
No comments:
Post a Comment